| scholarly article | Q13442814 |
| P50 | author | Giuseppe Marano | Q54230596 |
| Denisa Baci | Q55754927 | ||
| Elena De Falco | Q56930260 | ||
| Luca Madaro | Q83508004 | ||
| Marika Milan | Q86392715 | ||
| P2093 | author name string | Roberto Rizzi | |
| Pier Lorenzo Puri | |||
| Giacomo Frati | |||
| Claudia Bearzi | |||
| Sonia Maccari | |||
| Tonino Stati | |||
| Valentina Pace | |||
| Fabio Maiullari | |||
| Maila Chirivì | |||
| Silvia Maiullari | |||
| P2860 | cites work | Dysregulation of histone acetyltransferases and deacetylases in cardiovascular diseases | Q21284678 |
| CaM kinase II selectively signals to histone deacetylase 4 during cardiomyocyte hypertrophy | Q24293269 | ||
| Histone deacetylase (HDAC) inhibitors attenuate cardiac hypertrophy by suppressing autophagy | Q24603793 | ||
| Antifibrotic therapies to control cardiac fibrosis | Q26745841 | ||
| Management of fibrosis: the mesenchymal stromal cells breakthrough | Q26827231 | ||
| Cardiosphere conditioned media influence the plasticity of human mediastinal adipose tissue-derived mesenchymal stem cells. | Q51659834 | ||
| Safety and efficacy of an oral histone deacetylase inhibitor in systemic-onset juvenile idiopathic arthritis | Q61633704 | ||
| Transforming growth factor beta 1 induces apoptotic cell death in cultured human umbilical vein endothelial cells with down-regulated expression of bcl-2 | Q72269420 | ||
| Good and bad sides of TGFβ-signaling in myocardial infarction | Q26863465 | ||
| Molecular mechanisms of epithelial-mesenchymal transition | Q27013743 | ||
| Post-natal cardiomyocytes can generate iPS cells with an enhanced capacity toward cardiomyogenic re-differentation | Q30515858 | ||
| PlGF-MMP9-engineered iPS cells supported on a PEG-fibrinogen hydrogel scaffold possess an enhanced capacity to repair damaged myocardium | Q30573513 | ||
| Genetic lineage tracing defines myofibroblast origin and function in the injured heart | Q33908363 | ||
| The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo | Q34504770 | ||
| New generation small-molecule inhibitors in myeloproliferative neoplasms. | Q34634950 | ||
| Effects of the histone deacetylase inhibitor ITF2357 in autoinflammatory syndromes | Q35016951 | ||
| The oral histone deacetylase inhibitor ITF2357 reduces cytokines and protects islet β cells in vivo and in vitro | Q35017018 | ||
| Endothelial p53 deletion improves angiogenesis and prevents cardiac fibrosis and heart failure induced by pressure overload in mice | Q35135731 | ||
| Histone deacetylase 3 regulates smooth muscle differentiation in neural crest cells and development of the cardiac outflow tract | Q35576426 | ||
| Anti-Fibrotic Effects of Class I HDAC Inhibitor, Mocetinostat Is Associated with IL-6/Stat3 Signaling in Ischemic Heart Failure | Q35723859 | ||
| Histone deacetylases and cardiovascular cell lineage commitment | Q35774293 | ||
| Inhibition of histone deacetylases preserves myocardial performance and prevents cardiac remodeling through stimulation of endogenous angiomyogenesis | Q35847709 | ||
| Histone deacetylase inhibitors prevent exocytosis of interleukin-1beta-containing secretory lysosomes: role of microtubules | Q35849001 | ||
| Requirement for the histone deacetylase Hdac3 for the inflammatory gene expression program in macrophages | Q36342694 | ||
| ITF2357 transactivates Id3 and regulate TGFβ/BMP7 signaling pathways to attenuate corneal fibrosis | Q36569602 | ||
| Hypoxia-Inducible Factor (HIF)-1 regulatory pathway and its potential for therapeutic intervention in malignancy and ischemia | Q37045533 | ||
| HDAC inhibitors induce tumor-cell-selective pro-apoptotic transcriptional responses | Q37073624 | ||
| Histone deacetylase inhibitors as therapeutic agents for acute central nervous system injuries | Q37832963 | ||
| Therapeutic potential for HDAC inhibitors in the heart | Q37937667 | ||
| Oxidative stress and mitochondrial dysfunction in aluminium neurotoxicity and its amelioration: a review. | Q38190319 | ||
| Review article: selective histone deacetylase isoforms as potential therapeutic targets in inflammatory bowel diseases | Q38264859 | ||
| Histone deacetylase inhibitors: a potential epigenetic treatment for Duchenne muscular dystrophy. | Q38272315 | ||
| Role of innate and adaptive immune mechanisms in cardiac injury and repair | Q38329556 | ||
| Knockdown of SOX9 Inhibits the Proliferation, Invasion, and EMT in Thyroid Cancer Cells | Q38712987 | ||
| The Biological Basis for Cardiac Repair After Myocardial Infarction: From Inflammation to Fibrosis. | Q38875774 | ||
| Predictors of Ischemic Stroke in Rheumatic Heart Disease | Q38959776 | ||
| Metformin mediated reversal of epithelial to mesenchymal transition is triggered by epigenetic changes in E-cadherin promoter | Q39480588 | ||
| Transcriptional activation of cartilage oligomeric matrix protein by Sox9, Sox5, and Sox6 transcription factors and CBP/p300 coactivators | Q40136077 | ||
| The potential of GMP-compliant platelet lysate to induce a permissive state for cardiovascular transdifferentiation in human mediastinal adipose tissue-derived mesenchymal stem cells. | Q41901872 | ||
| Up-regulation of alpha-smooth muscle actin in cardiomyocytes from non-hypertrophic and non-failing transgenic mouse hearts expressing N-terminal truncated cardiac troponin I. | Q42846330 | ||
| Cardiac mast cells cause atrial fibrillation through PDGF-A-mediated fibrosis in pressure-overloaded mouse hearts | Q42946844 | ||
| Dose-dependent blockade to cardiomyocyte hypertrophy by histone deacetylase inhibitors | Q44449807 | ||
| BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury | Q44479221 | ||
| BMP-7 blocks the effects of TGF-β-induced EMT in cholangiocarcinoma | Q45083311 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P4510 | describes a project that uses | ImageJ | Q1659584 |
| P433 | issue | 2 | |
| P304 | page(s) | 108 | |
| P577 | publication date | 2018-01-25 | |
| P1433 | published in | Cell Death and Disease | Q2197222 |
| P1476 | title | Givinostat reduces adverse cardiac remodeling through regulating fibroblasts activation | |
| P478 | volume | 9 |
| Q92323965 | Endothelial to Mesenchymal Transition: Role in Physiology and in the Pathogenesis of Human Diseases |
| Q92465956 | Epigenetics in Cardiac Hypertrophy and Heart Failure |
| Q92324516 | HDAC inhibitors as antifibrotic drugs in cardiac and pulmonary fibrosis |
| Q90272942 | Neuroprotective mechanism of TMP269, a selective class IIA histone deacetylase inhibitor, after cerebral ischemia/reperfusion injury |
| Q64063293 | Regulation of Chemokines and Cytokines by Histone Deacetylases and an Update on Histone Decetylase Inhibitors in Human Diseases |
| Q98224256 | The Roles of Noncardiomyocytes in Cardiac Remodeling |
Search more.